Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. - Wikidata - awgldk - TriplyDB

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

http://www.wikidata.org/entity/Q33957588

about

The prediagnostic phase of Parkinson's disease Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.Illicit stimulant use is associated with abnormal substantia nigra morphology in humans Impaired trunk stability in individuals at high risk for Parkinson's disease A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Hyperechogenicity of the Substantia Nigra in Parkinson's Disease: Insights from Two Brothers with Markedly Different Disease Durations.Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes PREDICT-PD: identifying risk of Parkinson's disease in the community: methods and baseline results Neuroimaging in pre-motor Parkinson's disease Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson's disease Neuroimaging: current role in detecting pre-motor Parkinson's disease.The PRIPS study: screening battery for subjects at risk for Parkinson's disease.Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.Prodromal features for Parkinson's disease--baseline data from the TREND study.Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function Sonographic Alteration of Basal Ganglia in Different Forms of Primary Focal Dystonia: A Cross-sectional Study A delicate balance: Iron metabolism and diseases of the brain.PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.Motor signs in the prodromal phase of Parkinson's disease.Biomarkers of Parkinson's disease: current status and future perspectives.Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease.Is there a need to redefine Parkinson's disease?Recent developments in biomarkers in Parkinson disease Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.The relevance of pre-motor symptoms in Parkinson's disease.The Concept of Prodromal Parkinson's Disease.Advances in Biomarker Research in Parkinson's Disease.3D transcranial ultrasound as a novel intra-operative imaging technique for DBS surgery: a feasibility study.Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors.Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls.Biomarkers in Neurodegenerative Diseases.Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls Risk factors and prodromal markers and the development of Parkinson's disease.Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines.Transcranial sonography in idiopathic REM sleep behavior disorder and multiple system atrophy.Cognitive changes in prodromal Parkinson's disease: A review.

P2860

Q26768732-45166452-73D8-43D6-9BF0-B5C6F66D3FDF Q27686808-2E23D321-55CE-4F06-B966-8F0973B8589C Q28486143-0E72B102-F642-4548-A606-8D1FE0ECA7CD Q28730962-6EFF1027-9D38-464E-89EE-18C9E80C9ADE Q30240991-BE1F2F11-01A3-4292-9AB3-F46911F9FFEB Q30363964-7AC76D5F-542C-4E62-89BC-D73AB312EDCD Q30454441-C7EDB791-B73E-4D3F-BAAF-4AA8C2028DE1 Q30468731-48310146-4FBE-45B0-8309-F04964414390 Q30564071-4C48A5DB-19BE-4226-969A-81BEA3F1D5AA Q33676222-A228C2C4-36F6-4C39-80DF-B70B9F75B426 Q34066195-52CB1AB7-FAD4-4508-AD45-44D432AF55D4 Q34234625-BE2A38C5-4690-42DE-838F-F285DD0C219D Q34361343-04DCF65B-351F-4C0A-BF6E-A2B665A0C219 Q34372099-833641A0-2710-47AF-96DA-1F7CBB553F73 Q34463276-A7D4E27D-BBD7-4AB1-A91E-3E73DE833229 Q35115470-931C7842-7CAC-4C30-88FD-903BB9B694D4 Q35159798-6F92005A-2A84-485D-AC95-AFF678346EED Q36797812-439E10B3-6CC7-4C6C-99DA-E09DBAC7DBD8 Q37023585-8FCAB703-E95C-4AC5-A65C-E3C4AA5089F4 Q37663889-0C5172EB-AAF0-42D6-AF0E-5645656C2E43 Q37995956-2F6C915B-7148-476F-AE77-64B2217C4167 Q38043841-B390D968-A67A-455F-AD6E-9129B2A9F3D7 Q38045906-848BC54C-FFE0-4A68-9C38-FF931F82B2FC Q38110209-320CF514-17BF-40F9-9410-3EA9F3E57729 Q38119095-CBEB468E-7705-4F0B-A7B3-9F8CE8CF85A9 Q38501869-0D5F2022-DA86-448B-9052-C064B3F33D21 Q38594857-0C7097D7-48FA-4B9B-AF69-7A56AECDF054 Q38612230-68E6C888-86FB-46B6-8102-6D13E4A08AC4 Q38681599-CE080651-D06A-48BC-8EF5-0FA5CC5BAC2D Q39019480-B23B6A38-0B88-49FD-86BA-9E78BB61F22E Q39153958-A8C2722D-669F-4779-B9DD-F2B05E4B646B Q39202020-FB2D76A9-68BA-4A9A-BFDB-EC189614AAC3 Q39413097-12EC0DA3-D5FB-4B0C-BA84-F9873ED4D3CE Q41752929-B3CB823D-5A64-4845-8384-7D77F6D71666 Q41825693-FFF8B338-CA0F-4551-B663-03859E2303BC Q41992235-1BC17896-2009-4D85-8F79-02B27860877E Q44252207-C01AF414-835B-4656-9A56-CD50C89996BF Q46577527-CF5996AB-9BC5-404D-8D9F-EC3FCDE069A4 Q47789434-A505E171-CEB1-450D-A3F9-7B729DC7B080 Q47860019-99B9CBA4-86A2-4EE3-8989-42689946C75B

P2860

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

http://www.wikidata.org/entity/Q33957588

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@ast

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@en

type

label

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@ast

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@en

prefLabel

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@ast

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@en

P1433

Q33957588-7C94CF52-CAD7-489F-8F70-6464F56316F5

P1476

Q33957588-A5583FC8-E83D-4C23-AA70-9DCDBEBEA563

P2093

Q33957588-123ADE0A-3860-41F7-AAA8-483C03532A76

Q33957588-190C0088-147B-4726-BB0F-EE75525BF2B3

Q33957588-2517ED55-E8F6-473C-98FE-9FE194A39066

Q33957588-371394BD-6DD9-4C45-867A-FE57D74BA02C

Q33957588-3F4BD5E7-822D-4667-984D-F6120762937A

Q33957588-4399B4A5-0D2A-4F90-A2CF-B219EFEC10B3

Q33957588-4B174679-D566-414C-BCCA-8328431FBFA7

Q33957588-4EA9A10A-4AA1-48A6-A28C-6AEADB81370E

Q33957588-9AA8065A-1FB0-4503-95E0-525DEE89BF29

Q33957588-9BBB1158-54C7-4D25-8A5A-E65BEE804576

P304

Q33957588-4C903BAC-248A-46FF-B27B-197A52DDB767

P31

Q33957588-00219236-FAFE-483C-930C-5CAEC24CD254

P356

Q33957588-146DD7B6-0870-4E71-A38C-877715C4FF33

P433

Q33957588-A0DBBC27-1CA1-466A-A446-899E284E2BC6

P478

Q33957588-A527B67A-7D77-4AF0-AE50-2F0A58BD3222

P50

Q33957588-04787C04-A192-4DED-9991-A15578E44E2E

Q33957588-3FC8ACAE-791D-4F17-910C-326B2E817BFF

Q33957588-B43F44D9-F9AD-49A3-BEFD-D3C34A4E1CA7

Q33957588-CACC1E91-7BB4-4B4B-A2EA-7C9BE4822CF2

Q33957588-E71E0146-8ECE-4780-B5E8-EB4E62DB6FB5

Q33957588-EC9D2C87-4232-4A6E-B8DF-F44E0231D7D5

Q33957588-EFEB5958-308E-4CAA-B5C0-E6EFE2FDB306

Q33957588-F7B95ADA-B37B-42AA-8425-1A71A3FE7555

P577

Q33957588-B6CEFF3F-3909-4393-8061-78658E5FC204

P5875

Q33957588-50CEFFDF-D49B-4CB1-A8CE-A447D810E350

P698

Q33957588-03864E96-80AE-4113-AD7D-6CC1A82E7D92

P921

Q33957588-52A46E3E-D457-4AEB-AB01-EC3E87C5ACEB

Q33957588-9625AFF6-814A-4C2C-B102-5F43E3B8654C

P356

ARCHNEUROL.2011.141

P1433

P1476

Enlarged substantia nigra hype ...... r study of 1847 older persons.

@en

P2093

Alexandra Gaenslen

http://www.w3.org/2001/XMLSchema#string

Arno Gasperi

http://www.w3.org/2001/XMLSchema#string

Frank Wollenweber

http://www.w3.org/2001/XMLSchema#string

Heike Stockner

http://www.w3.org/2001/XMLSchema#string

Heiko Huber

http://www.w3.org/2001/XMLSchema#string

Inga Liepelt

http://www.w3.org/2001/XMLSchema#string

Jana Godau

http://www.w3.org/2001/XMLSchema#string

Johann Willeit

http://www.w3.org/2001/XMLSchema#string

Jörg Spiegel

http://www.w3.org/2001/XMLSchema#string

Karin Srulijes

http://www.w3.org/2001/XMLSchema#string

P304

932-937

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2011.141

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Klaus Fassbender

Philipp Mahlknecht

Walter Maetzler

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51483658

http://www.w3.org/2001/XMLSchema#string

P698

21747034

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

substantia nigra